Dendreon Receives FDA Approval for Provenge
Dendreon shares closed Thursday up 26% to $50.18. The stock was halted for a time at $45.50 soon after the announcement hit the tape.
Provenge becomes the first cancer drug approved that works by activating a patient's own immune system to fight the disease. Under the FDA approval, Dendreon will market Provenge as a treatment for men with advanced prostate cancer that has grown resistant to standard hormone treatment.
"The FDA approval of Provenge is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees," said Dendreon CEO Mitch Gold, in a statement.Provenge was approved based on a pivotal study in 512 men demonstrating that treatment with Provenge could extend survival by 4.1 months compared to patients not treated with Provenge. "The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Dr. Karen Midthun, acting director of the FDA's Center for Biologics Evaluation and Research, in a statement. Dendreon's struggles to bring Provenge to market have been long documented. An FDA advisory panel in 2007 recommended Provenge's approval but the FDA later decided to request more clinical data. Dendreon then ran another clinical trial that produced positive results in April 2009 and allowed the company to refile Provenge with FDA. Dendreon is expected to treat its first prostate cancer patient with Provenge in the nect week. The company announced a Provenge treatment price of $93,000, well above Street estimates. Analysts have estimated the drug could generate $1 billion or more in U.S. sales, but that forecast may rise now given the higher Provenge sales price. The commercial launch of Provenge will be closely watched because the drug is no ordinary off-the-shelf cancer drug. Instead, Provenge is personalized for each individual prostate cancer patient. This adds a logistical complexity to the manufacture and delivery of Provenge that could cause Dendreon some problems, or at least some sleepless nights, in the first days and weeks of the drug's launch. Wall Street will be watching the Provenge launch closely. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV